LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $15.00

LifeStance Health Group (NASDAQ:LFST) had its price objective hoisted by JPMorgan Chase & Co. from $13.00 to $15.00 in a research note issued to investors on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

LFST has been the topic of a number of other research reports. Wall Street Zen downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. BTIG Research boosted their price objective on shares of LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of LifeStance Health Group in a research report on Wednesday, November 4th. Canaccord Genuity Group increased their price objective on shares of LifeStance Health Group from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Finally, KeyCorp raised their target price on shares of LifeStance Health Group from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.86.

LifeStance Health Group Stock Down 0.5%

Shares of LFST stock traded down $0.07 during mid-day trading on Thursday, hitting $14.08. The company’s stock had a trading volume of 3,728,905 shares, compared to its average volume of 6,598,220. The stock has a market cap of $5.35 billion, a price-to-earnings ratio of 74.11 and a beta of 1.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.44 and a current ratio of 1.44. LifeStance Health Group has a 52-week low of $6.01 and a 52-week high of $15.66. The business has a 50-day moving average price of $12.79 and a 200 day moving average price of $9.67.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The company had revenue of $455.86 million for the quarter, compared to analysts’ expectations of $431.59 million. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year. Research analysts predict that LifeStance Health Group will post 0.18 EPS for the current fiscal year.

Insider Activity

In related news, CTO Vukasin Paunovich sold 42,067 shares of LifeStance Health Group stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total transaction of $541,402.29. Following the transaction, the chief technology officer directly owned 205,379 shares in the company, valued at approximately $2,643,227.73. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Lisa K. Miller sold 14,663 shares of the business’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $14.68, for a total value of $215,252.84. Following the sale, the chief operating officer directly owned 251,904 shares of the company’s stock, valued at $3,697,950.72. This represents a 5.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 2,861,235 shares of company stock valued at $41,646,338 in the last 90 days. Company insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP grew its stake in shares of LifeStance Health Group by 511.8% during the 3rd quarter. Marshall Wace LLP now owns 9,955,435 shares of the company’s stock valued at $119,764,000 after acquiring an additional 8,328,169 shares during the period. Kovack Advisors Inc. bought a new stake in LifeStance Health Group during the 3rd quarter worth approximately $177,000. Caxton Associates LLP lifted its holdings in LifeStance Health Group by 164.2% during the third quarter. Caxton Associates LLP now owns 246,423 shares of the company’s stock valued at $2,964,000 after purchasing an additional 153,169 shares in the last quarter. First Trust Advisors LP lifted its holdings in LifeStance Health Group by 62.6% during the third quarter. First Trust Advisors LP now owns 1,438,471 shares of the company’s stock valued at $17,305,000 after purchasing an additional 553,736 shares in the last quarter. Finally, Advisors Asset Management Inc. purchased a new position in LifeStance Health Group during the third quarter valued at approximately $64,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.